Literature DB >> 23806547

Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum.

Florian Custodis1, Jan-Christian Reil, Ulrich Laufs, Michael Böhm.   

Abstract

Heart rate is a predictor of cardiovascular and all-cause mortality in the general population and in patients with cardiovascular disease. Increased resting heart rate multiplies risk and interferes at all stages of the cardiovascular disease continuum initiating from endothelial dysfunction and continuing via atherosclerotic lesion formation and plaque rupture to end-stage cardiovascular disease. As a therapeutic target, heart rate is accessible via numerous pharmacological interventions. The concept of selective heart rate reduction by the I(f) current inhibitor ivabradine provides an option to intervene effectively along the chain of events and to define the specific and prognostic role of heart rate for patients with coronary artery disease and heart failure. Future interventional studies will further clarify the significance of heart rate and targeted heart rate reduction for primary and secondary prevention in cardiovascular and cerebrovascular events.
Copyright © 2013 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease continuum; Heart rate; I(f) current inhibition; Risk reduction

Mesh:

Substances:

Year:  2013        PMID: 23806547     DOI: 10.1016/j.jjcc.2013.02.018

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  16 in total

Review 1.  Novel and nonpharmacologic approaches to cardio-protection in hypertension.

Authors:  Luca Donazzan; Felix Mahfoud; Dominik Linz; Sebastian Ewen; Christian Ukena; Michael Böhm
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

Review 2.  Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction.

Authors:  Gerd Heusch; Petra Kleinbongard
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 3.  The therapeutic role of ivabradine in heart failure.

Authors:  Charles Badu-Boateng; Robert Jennings; Daniel Hammersley
Journal:  Ther Adv Chronic Dis       Date:  2018-07-04       Impact factor: 5.091

4.  Novel association of the obesity risk-allele near Fas Apoptotic Inhibitory Molecule 2 (FAIM2) gene with heart rate and study of its effects on myocardial infarction in diabetic participants of the PREDIMED trial.

Authors:  Dolores Corella; Jose V Sorlí; José I González; Carolina Ortega; Montserrat Fitó; Monica Bulló; Miguel Angel Martínez-González; Emilio Ros; Fernando Arós; José Lapetra; Enrique Gómez-Gracia; Lluís Serra-Majem; Valentina Ruiz-Gutierrez; Miquel Fiol; Oscar Coltell; Ernest Vinyoles; Xavier Pintó; Amelia Martí; Carmen Saiz; José M Ordovás; Ramón Estruch
Journal:  Cardiovasc Diabetol       Date:  2014-01-06       Impact factor: 9.951

Review 5.  The end effector of circadian heart rate variation: the sinoatrial node pacemaker cell.

Authors:  Yael Yaniv; Edward G Lakatta
Journal:  BMB Rep       Date:  2015-12       Impact factor: 4.778

6.  Ambulatory heart rate of professional taxi drivers while driving without their typical psychosocial work stressors: a pilot study.

Authors:  BongKyoo Choi; SangJun Choi; JeeYeon Jeong; JiWon Lee; Shi Shu; Nu Yu; SangBaek Ko; Yifang Zhu
Journal:  Ann Occup Environ Med       Date:  2016-10-06

Review 7.  If Channel as an Emerging Therapeutic Target for Cardiovascular Diseases: A Review of Current Evidence and Controversies.

Authors:  Hayelom G Mengesha; Tadesse B Tafesse; Mohammed H Bule
Journal:  Front Pharmacol       Date:  2017-11-24       Impact factor: 5.810

8.  Nocturnal heart rate and inflammation.

Authors:  Yuichiro Yano; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-10-13       Impact factor: 3.738

9.  The product of resting heart rate times blood pressure is associated with high brachial-ankle pulse wave velocity.

Authors:  Anxin Wang; Jie Tao; Xiuhua Guo; Xuemei Liu; Yanxia Luo; Xiurong Liu; Zhe Huang; Shuohua Chen; Xingquan Zhao; Jost B Jonas; Shouling Wu
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  Elevated resting heart rate is a marker of subclinical left ventricular dysfunction in hodgkin lymphoma survivors.

Authors:  Julius C Heemelaar; Augustinus D G Krol; Marloes Louwerens; Saskia L M A Beeres; Eduard R Holman; Martin J Schalij; M Louisa Antoni
Journal:  Int J Cardiol Heart Vasc       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.